{"id":"W3179168710","doi":"10.1158/1538-7445.am2021-ct252","title":"Abstract CT252: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naïve Myelofibrosis","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Gastroenterology; Placebo; International Prognostic Scoring System; Polycythemia vera; Randomization; Anemia; Randomized controlled trial; Surgery; Bone marrow; Myelodysplastic syndromes; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001516563,0.002364252,0.003143495,0.000624606,0.0007403338,0.001442077,0.001361869,0.00208796,0.01337693],"category_scores_gemma":[0.00131079,0.0008955584,0.001912678,0.0005284044,0.001246811,0.001208186,0.0003369694,0.003363195,0.002127473],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008856124,"about_ca_system_score_gemma":0.001826132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001351749,"about_ca_topic_score_gemma":0.00351277,"domain_scores_codex":[0.9994235,0.00026021,0.00004322968,0.0001175696,0.00005261159,0.0001028316],"domain_scores_gemma":[0.9993512,0.00009534373,0.0001256017,0.00003615552,0.0000499659,0.0003417674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9650686,0.012232,0.0003726714,0.0008269386,0.001074247,0.00008180547,0.00004259688,0.0003256749,0.007200766,0.0001206521,0.001969261,0.01068467],"study_design_scores_gemma":[0.9582711,0.03986193,0.0007531216,0.00002121206,0.0001900312,0.00002313913,0.00001037325,0.000175101,0.0002635013,0.00004434345,0.0003747638,0.00001121134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9640992,0.008266889,0.001289842,0.001429927,0.001192789,0.01418146,0.003804413,0.0005368167,0.005198775],"genre_scores_gemma":[0.976255,0.002534059,0.001674351,0.002194541,0.0005100557,0.009027973,0.002504844,0.000035772,0.005263367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01337693,"threshold_uncertainty_score":0.04475027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08149661003398903,"score_gpt":0.4138220584246176,"score_spread":0.3323254483906285,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}